Xalud Therapeutics is a clinical-stage biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.
Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to address pathologic inflammation and pain. Xalud is currently evaluating XT-150 across multiple treatment indications in preclinical and clinical studies.